Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Mechanisms of drugs-resistance in small cell lung cancer II

ABSTRACT: Mechanisms of drugs-resistance in small cell lung cancer II

PROVIDER: PRJNA846261 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR19546010.fastq.gz	Fastqsanger.gz
	SRR19546011.fastq.gz	Fastqsanger.gz
	SRR19546012.fastq.gz	Fastqsanger.gz
	SRR19546013.fastq.gz	Fastqsanger.gz
	SRR19546014.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 9

Similar Datasets

Mechanisms of drugs-resistance in small cell lung cancer

Project description:Mechanisms of drugs-resistance in small cell lung cancer

| PRJNA706414 | ENA

Mechanisms of drugs-resistance in small cell lung cancer III

Project description:Mechanisms of drugs-resistance in small cell lung cancer III

| PRJNA1177374 | ENA

Mechanisms of drugs-resistance in small cell lung cancer II

Project description:Malignant transformation of SCLC often occurs simultaneously with the acquisition of chemotherapy resistance, suggesting that phenotypic malignant transformation is associated with adaptation to chemotherapy-induced stress. Recently, it has been reported that autophagy deficiency is involved in chemotherapy resistance in SCLC. To analyze gene expression changes associated with SCLC malignant transformation, we established ATG7 knockout and ATG7/SQSTM1 double knockout SCLC cell lines and performed RNA sequencing.

2022-06-11 | GSE205522 | GEO

Mechanisms of drugs-resistance in small cell lung cancer

Project description:Lung cancer is the leading cause of cancer mortality and is classified by the World Health Organization into two broad histological subtypes. Non–small cell lung cancer (NSCLC), including adenocarcinoma, squamous cell carcinoma, and large cell carcinoma, accounts for ~85% of all lung cancer cases, with the remaining 15% of cases being due to small cell lung cancer (SCLC), which arises from neuroendocrine cells in the lung. Although most SCLC tumors are initially responsive to chemotherapy and radiation, patients often experience relapse, with the tumor acquiring an aggressiveness and therapeutic resistance that lead to a poor clinical outcome. Improvement of overall survival in individuals with SCLC will require the identification of novel therapeutic targets based on a better understanding of the changes in intracellular signaling of aggressive SCLC cells. The malignant progression of SCLC often occurs concomitantly with the acquisition of chemoresistance, suggesting that phenotypic malignant change is related to adaptation to the stresses induced by chemotherapy. In order to analyze gene expression changes associated with malignant transformation in SCLC, we established a cisplatin-resistant SCLC cell line and performed RNA sequencing.

2021-03-04 | GSE168184 | GEO

Mechanisms of drugs-resistance in small cell lung cancer III

2025-03-31 | GSE280212 | GEO

Specificity, synergy, and mechanisms of splice-modifying drugs

Project description:Specificity, synergy, and mechanisms of splice-modifying drugs

| PRJNA916518 | ENA

Genomic and Functional Identification of Chemotherapy Resistance Mechanisms in Small Cell Lung Cancer

Project description:Genomic and Functional Identification of Chemotherapy Resistance Mechanisms in Small Cell Lung Cancer

| PRJNA1188211 | ENA

Genomic and Functional Identification of Chemotherapy Resistance Mechanisms in Small Cell Lung Cancer

Project description:Genomic and Functional Identification of Chemotherapy Resistance Mechanisms in Small Cell Lung Cancer

| PRJNA1188210 | ENA

Molecular mechanisms and potential therapeutic drugs linking to cetuximab-resistance reactions in cancer cells

Project description:Molecular mechanisms and potential therapeutic drugs linking to cetuximab-resistance reactions in cancer cells

| PRJNA473145 | ENA

Specificity, synergy, and mechanisms of splice-modifying drugs

Project description:Drugs that target pre-mRNA splicing hold great therapeutic potential, but the mechanistic understanding of how these drugs function is limited. Here we introduce a biophysical modeling framework that can quantitatively describe the sequence-specific and concentration-dependent behavior of splice-modifying drugs. Using massively parallel splicing assays, RNA-seq experiments, and precision dose-response curves, we apply this framework to two drugs, risdiplam and branaplam, developed for treating spinal muscular atrophy. The results quantitatively define the specificities of risdiplam and branaplam for 5’ splice site sequences, suggest that branaplam recognizes 5’ splice sites via two distinct interaction modes, and disprove the prevailing two-site hypothesis for risdiplam activity at SMN2 exon 7. The results also show, more generally, that single-drug cooperativity and multi-drug synergy are widespread among splice-modifying drugs. Our biophysical modeling approach thus clarifies the mechanisms of existing splice-modifying treatments and provides a quantitative basis for the rational development of new therapies.

2023-01-09 | GSE221868 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data